This is a snippet of the transcript, sign up to read more.
Labs need to be on high streets, visible on main roads, as that strategy works. If a lab is hidden, it doesn't succeed. Being on main roads is crucial for a consumer brand, which is what they aim to be. Visibility is important for long-term success; otherwise, you must spend heavily on promotion. It's better to be on accessible, visible high streets, especially for the B2C model that Dr. Lal follows.
This is a snippet of the transcript, sign up to read more.
This is what's called a hub and spoke model, where you have a reference lab, satellite labs, collection centers, a logistics team to transport samples, and a home collection team to pick up samples from homes. Dr. Lal, when they went the B2C route, treated it more like a consumer business. They reached out to the last-mile consumer through home collection. The idea was convenience, so the customer didn't need to leave home. Samples would be picked up at their convenience, and reports would be sent via email or an app. This brought a lot of convenience, which is now a standard practice. All the big labs do that.
This is a snippet of the transcript, sign up to read more.
You can have thousands of samples in small vacutainers, which don't weigh much, so you really don't pay a lot. That's the innovation of the Thyrocare founder. He realized that millions of samples don't incur significant costs, which is more efficient than opening 200 labs and spending more money. He conducted a cost-benefit analysis and was the only one thinking in this disruptive way. He introduced a new business model by transporting samples via airplane instead of by road, reducing manpower and administrative costs. Manpower and admin are the largest costs in diagnostics, consuming around 40% of your gross margin. That's why EBITDA is around 10%, with a gross margin of 60% and operating expenses of 40% to 45%. By avoiding these costs, the profit and loss statement improves.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research